Peptide API Manufacturing: AI Market Discovery Index

Tracking how AI platforms recommend peptide api manufacturing. This public AI Market Discovery Index is updated monthly since July 2026.

By Mark Huntley, J.D.Growth Strategist & AI Discovery Analyst

5 minutes read

Get my free AI Company Index Download sample PDF

On this page

01Benchmark Summary
02Current Benchmark at a Glance
03Research Scope and Qualification
04Current Brand Standings
05How to Read the Standings
06Recommendation Coverage Movement
07Largest Decline: AmbioPharm
08Largest Decline: Biosynth Peptide Division
09Category Leader: Bachem
10Recommendation Placement Snapshot
11Buyer-Intent Distribution
12Historical Measurement Record

Benchmark Summary

Bachem led the Peptide API Manufacturing benchmark in September 2026 with valid recommendation coverage of 36.2%, down from 42.2% in July 2026. The gap to the next brand stood at 25.7 percentage points over AmbioPharm, which held 10.5% coverage in September 2026, down from 21.8% in July 2026. The largest coverage decline belonged to AmbioPharm, falling from 21.8% in July 2026 to 10.5% in September 2026. There were no coverage increases of note; Biosynth Peptide Division declined from 12.4% in July 2026 to 6.2% in September 2026.

Across the full series, Bachem has held the leadership position in all three months, though its September 2026 figure of 36.2% compares with 42.2% in July 2026 and 44.8% in August 2026. The benchmark began with 373 prompt-surface observations in September 2026 and produced 257 qualified observations after qualification.

AI recommendation trend

valid recommendation coverage, Jul 2026 to Sep 2026

Bachem36.2%
AmbioPharm10.5%
Biosynth Peptide Division6.2%
PolyPeptide Group5.8%
CPC Scientific5.5%
CordenPharma Peptides2.7%
CSBio1.6%

Current Benchmark at a Glance

Measure	Jul 2026	Sep 2026	Movement
Qualified benchmark observations	225	257	Up 32
Tracked brands	7	7	No change
Qualified surface breadth	6	6	No change
Recommendation-shaped answer share	38.2%	21.4%	Down 16.8 points
Valid recommendation shortlist share	43.1%	32.3%	Down 10.8 points
Leader by valid recommendation coverage	Bachem (42.2%)	Bachem (36.2%)	Down 6.0 points

Qualified surface breadth counts the canonical AI/search surface families with at least one qualified observation, rolling keyword variants into their parent families. The six canonical families are ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.

For the strategic interpretation of this benchmark, read CiteWorks Studio's analysis of How AI Search Is Recommending Peptide API Manufacturing

Research Scope and Qualification

The public benchmark is narrower than the raw collection universe by design.

Research stage	Jul 2026	Sep 2026	What it represents
Source prompt-surface observations	280	373	Total prompt-surface observations collected
Unique questions	194	236	Distinct questions asked
Brand / competitor mentions	280	373	Prompts mentioning a brand or competitor
Relevant observations	253	331	Observations relevant to the vertical
Irrelevant observations	27	42	Observations deemed irrelevant
Qualified benchmark observations	225	257	Public denominator for brand metrics

Brand-level percentages use the qualified observations as the public denominator, not the raw collection. See AI Market Discovery Methodology.

Current Brand Standings

Want the full Authority Index

The paid deep-dive adds competitor threat profiles, the gap matrix, citation failure map, platform-by-platform recovery roadmap, and client-specific economic modeling.

Request free AI Company Index

Brand	Presence rate	Valid recommendation coverage	Top-three rate	Rank-one rate	Net sentiment
Bachem	92.6%	36.2%	25.3%	14.8%	0.88
AmbioPharm	39.3%	10.5%	5.1%	1.2%	0.90
Biosynth Peptide Division	15.2%	6.2%	4.7%	0.8%	1.00
PolyPeptide Group	26.1%	5.8%	1.9%	0.0%	0.93
CPC Scientific	14.0%	5.5%	0.8%	0.0%	0.86
CordenPharma Peptides	10.9%	2.7%	0.8%	0.0%	0.79
CSBio	3.5%	1.6%	0.8%	0.0%	0.89

How to Read the Standings

Presence rate is the share of qualified observations in which the brand is mentioned at all. Valid recommendation coverage is the share of qualified observations in which the brand receives a valid recommendation. Top-three rate is the share of qualified observations in which the brand appears in the first three recommended positions. Rank-one rate is the share of qualified observations in which the brand is the first recommendation. Net sentiment is the balance of positive over negative mentions among observations where the brand is present.

For formulas and denominator rules, see AI Market Discovery Metric Definitions.

Recommendation Coverage Movement

Brand	Jul 2026	Sep 2026	Movement since baseline
AmbioPharm	21.8%	10.5%	Down 11.3 points
Bachem	42.2%	36.2%	Down 6.0 points
Biosynth Peptide Division	12.4%	6.2%	Down 6.2 points
CordenPharma Peptides	3.6%	2.7%	Down 0.9 points
CPC Scientific	7.6%	5.5%	Down 2.1 points
CSBio	3.1%	1.6%	Down 1.5 points
PolyPeptide Group	9.8%	5.8%	Down 4.0 points

August 2026 was a quiet month with no brand moving beyond normal variation, but September 2026 brought significant movement. AmbioPharm and Biosynth Peptide Division registered the only moves beyond normal month-to-month variation on valid recommendation coverage across the baseline-to-current series. Bachem's coverage declined from 44.8% in August 2026 to 36.2% in September 2026, an 8.6-point move beyond normal variation, though its classification remains stable across the full series.

Largest Decline: AmbioPharm

AmbioPharm fell to 10.5% valid recommendation coverage in September 2026, down from 21.8% in July 2026 and down from 19.1% in August 2026. The brand declined in each of the two months since July 2026. Its top-three rate fell from 15.1% in July 2026 to 5.1% in September 2026, also beyond normal variation. Presence rate moved from 42.2% to 39.3% over the same period.

Largest Decline: Biosynth Peptide Division

Biosynth Peptide Division fell to 6.2% valid recommendation coverage in September 2026, down from 12.4% in July 2026 and down from 8.9% in August 2026. The brand declined in each of the two months since July 2026. Its presence rate declined from 26.2% in July 2026 to 15.2% in September 2026, a move beyond normal variation. Top-three and rank-one rates both rose modestly over the same period.

Want the full Authority Index

The paid deep-dive adds competitor threat profiles, the gap matrix, citation failure map, platform-by-platform recovery roadmap, and client-specific economic modeling.

Request free AI Company Index

Category Leader: Bachem

Bachem held the leadership position in all three months, with valid recommendation coverage of 42.2% in July 2026, 44.8% in August 2026, and 36.2% in September 2026. Though its coverage declined in September, its presence rate rose from 91.1% in July 2026 to 92.6% in September 2026. The gap over the second-place brand stood at 25.7 percentage points in September 2026.

Recommendation Placement Snapshot

Coverage alone does not show how prominently a brand is recommended. Among the leading cluster of Bachem and AmbioPharm, placement patterns diverged meaningfully in September 2026.

Brand	Sep 2026 top-three rate	Sep 2026 rank-one rate	Jul 2026 top-three rate	Jul 2026 rank-one rate
Bachem	25.3%	14.8%	35.6%	22.2%
AmbioPharm	5.1%	1.2%	15.1%	1.8%

Close coverage can still hide different first-position rates. Bachem's rank-one rate of 14.8% in September 2026 was well above AmbioPharm's 1.2%, despite both brands showing declining coverage from July.

Buyer-Intent Distribution

All qualified observations in both months fell into the Brand Recommendation class of discovery.

Buyer-intent class	Jul 2026	Sep 2026
Brand Recommendation	225	257
Pricing & Value	0	0
Multi-Brand Comparison	0	0
Total qualified observations	225	257

The current public series measures the Brand Recommendation class of discovery and does not yet contain qualified observations in the Pricing & Value or Multi-Brand Comparison classes.

Historical Measurement Record

This is an evergreen benchmark URL. New measurements are added to the same report.

Measurement	Qualified observations	Coverage leader	Leader coverage	Largest coverage movement
Jul 2026	225	Bachem	42.2%	21.8% (AmbioPharm)
Aug 2026	257	Bachem	44.8%	3.5 points down (Biosynth Peptide Division)
Sep 2026	257	Bachem	36.2%	11.3 points down (AmbioPharm)

Evidence and Source Layer

The benchmark is built from prompt-level observations that retain the query, AI/search surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources. Source presence is evidence about the information environment. It is not automatically proof that the source caused the recommendation.

Scope Boundaries

This public benchmark does not measure market share, attributable sales, every possible AI response, organic-search ranking, social mention volume, private or sponsored channels, or causality from a metric movement alone. It tracks how AI-powered discovery surfaces present brands within the Peptide API Manufacturing category, based on the qualified observation set defined above.

About This Benchmark

The LLM Authority Index AI Market Discovery Index tracks how AI-powered discovery surfaces present brands within a vertical, measuring presence, recommendation coverage, placement, and sentiment across six canonical AI/search surface families. The benchmark is updated monthly with a consistent methodology.

Get a Company-Level Authority Index

The public industry benchmark shows category-level standings. A company-level Authority Index can go deeper.

Get my free AI Company Index

Want the full Authority Index

The paid deep-dive adds competitor threat profiles, the gap matrix, citation failure map, platform-by-platform recovery roadmap, and client-specific economic modeling.

Request free AI Company Index